Cytovation ASA announced a new phase IIa expansion arm of the CICILIA trial examining the efficacy of its targeted tumor membrane immunotherapy CyPep-1 in treating patients with advanced melanoma refractory to immune checkpoint inhibitors, according to a report from Labiotech. Already demonstrating safety and efficacy as a monotherapy for several tumor types in a phase I trial, CyPep-1 works by encouraging an immune response following intratumoral injection. “We continue to be very pleased with the clinical development progress of CyPep-1 and are excited to be launching this phase IIa expansion arm, building upon our strong phase I monotherapy data,” concluded Lars Prestegarden, MD, PhD, Chief Executive Officer of Cytovation ASA. The researchers hope that with continued positive results, they can further test CyPep-1 as a monotherapy and in combination with pembrolizumab in subsequent phase II trials.
May 25, 2023